Dev4All, 4P-Pharma’s advanced research and development (R&D) booster, has partnered with Pharmaseed to enhance preclinical development services.
Pharmaseed is a contract research organisation (CRO) with expertise in preclinical drug development.
This collaboration combines the strengths of both firms to provide a seamless, end-to-end approach to preclinical development.
Together, Dev4All and Pharmaseed will aim to accelerate drug development and offer comprehensive and competitive solutions to meet the challenges of modern R&D.
Dev4All executive chair Revital Rattenbach said: “I am thrilled about the new collaboration between Dev4All and Pharmaseed, which marks an exciting step forward in our shared commitment to innovation.
“This commercial cooperation empowers us to scale our capabilities, elevate our global impact, and deliver tailor-made solutions that meet our client’s needs while maintaining the highest standards of scientific rigour.”
The commercial cooperation has over 20 years of CRO experience and a decade of advancing drug candidates from technology readiness level (TRL) 3 to 5.
In addition, this partnership offers customised preclinical support, state-of-the-art laboratory capabilities, and strategic expertise, enhancing the global R&D efforts of their clients.
Pharmaseed co-CEO Shmuel Landau said: “This collaboration with Dev4All is an excellent opportunity to expand our European presence and integrate our comprehensive preclinical solutions with DEV4ALL innovative R&D platform.
“Together, we are committed to deliver top-tier services, ensuring clients achieve their scientific and clinical milestones.”
Dev4All, powered by 4P-Pharma, is an R&D booster offering diverse preclinical solutions.
The company focuses on transforming new ideas into clinical-stage candidates through collaboration and scientific excellence.
Recently, Arrowhead Pharmaceuticals and Sarepta Therapeutics signed a global licensing and collaboration agreement to develop clinical and preclinical programmes. The deal includes several clinical and preclinical programmes targeting rare genetic diseases of the muscle, central nervous system, and lungs.
